Table 1.
Data collected at initial evaluation.
| Demographic data |
|---|
| Age |
| Sex |
| Ethnicity |
| Clinical data |
| Time of onset of erythroderma to the first evaluation |
| Previous cutaneous diseases |
| Exposition to new medications or possible allergens |
| Comorbidities |
| Weight loss |
| Pruritus |
| Non-scarring diffuse alopecia |
| Palmo-plantar keratoderma |
| Ungueal alterations |
| Ectropion |
| Lower limb edema |
| Mucosal lesions |
| Achromic vitiligo-like lesions |
| Spared areas |
| Lymph node enlargement |
| Hepatosplenomegaly |
| Temperature |
| Heart rate |
| Respiratory rate |
| Blood pressure |
| Laboratory tests |
| Complete blood count (leukocytosis if ≥ 11,000/mm3; lymphocytosis if ≥ 3,400/mm3; eosinophilia if ≥ 500/mm3) |
| Immunophenotyping of lymphocytes by flow cytometry8 |
| Sézary cell count in peripheral blood smear68 |
| T-cell receptor (TCR) gene rearrangement analysis by PCR in the blood9 |
| Lactate dehydrogenase |
| Protein electrophoresis |
| Total IgE |
| HIV serology |
| HTLV 1/2 serology69 |
| Three simultaneous skin biopsies to histology |
| One skin biopsy to TCR gene rearrangement analysis |
| Computed tomography (CT) of thorax, abdomen, and pelvis |
| Lymph-node excisional biopsy if ≥ 1.5 cm, or if abnormal characteristics are found (firm, irregular, clustered, or fixed) |